Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 31.47% is 37% above its 5-year average of 22.95%, near the high end of its 5-year range (10.62%–31.47%).
As of the fiscal period ended Wednesday, December 31, 2025. 8.78% above its 12-month average of 28.93%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
31.47%
RETURN ON EQUITY (ROE) AVG TTM
28.93%
RETURN ON EQUITY (ROE) AVG 3Y
25.01%
RETURN ON EQUITY (ROE) AVG 5Y
22.95%
RETURN ON EQUITY (ROE) AVG 10Y
6.26%
RETURN ON EQUITY (ROE) AVG 15Y
-11.66%
RETURN ON EQUITY (ROE) AVG 20Y
-18.38%
CURRENT VS TTM AVG
+8.78%
CURRENT VS 3Y AVG
+25.82%
CURRENT VS 5Y AVG
+37.13%
CURRENT VS 10Y AVG
+402.72%
CURRENT VS 15Y AVG
+369.84%
CURRENT VS 20Y AVG
+271.20%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+188.98%
vs the sector median at left
DexCom, Inc.
Market Cap
$27.61B
Return on Equity (ROE)
31.47%
TTM Avg
28.93%
3Y Avg
25.01%
5Y Avg
22.95%
Market Cap
$27.56B
Return on Equity (ROE)
14.11%
TTM Avg
21.84%
3Y Avg
21.53%
5Y Avg
32.27%
Market Cap
$28.33B
Return on Equity (ROE)
23.41%
TTM Avg
22.23%
3Y Avg
22.34%
5Y Avg
21.79%
Market Cap
$26.82B
Return on Equity (ROE)
-3677.41%
TTM Avg
-2178.82%
3Y Avg
-341.14%
5Y Avg
-117.12%
Market Cap
$29.85B
Return on Equity (ROE)
7.36%
TTM Avg
8.42%
3Y Avg
11.86%
5Y Avg
16.52%
Market Cap
$25.15B
Return on Equity (ROE)
18.49%
TTM Avg
13.34%
3Y Avg
14.07%
5Y Avg
18.07%
Market Cap
$24.42B
Return on Equity (ROE)
2.94%
TTM Avg
29.98%
3Y Avg
64.02%
5Y Avg
111.55%
Market Cap
$24.34B
Return on Equity (ROE)
10.79%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$31.31B
Return on Equity (ROE)
-30.07%
TTM Avg
-10.46%
3Y Avg
-1.37%
5Y Avg
1.10%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $27.61B | 31.47% | 28.93% | 25.01% | 22.95% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $27.56B | 14.11% | 21.84% | 21.53% | 32.27% |
| ResMed Inc. (RMD)vs › | $28.33B | 23.41% | 22.23% | 22.34% | 21.79% |
| Mettler-Toledo International Inc. (MTD)vs › | $26.82B | -3677.41% | -2178.82% | -341.14% | -117.12% |
| Biogen Inc. (BIIB)vs › | $29.85B | 7.36% | 8.42% | 11.86% | 16.52% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.15B | 18.49% | 13.34% | 14.07% | 18.07% |
| Waters Corporation (WAT)vs › | $24.42B | 2.94% | 29.98% | 64.02% | 111.55% |
| Labcorp Holdings Inc. (LH)vs › | $24.34B | 10.79% | 9.71% | 9.35% | 12.84% |
| Centene Corp. (CNC)vs › | $31.31B | -30.07% | -10.46% | -1.37% | 1.10% |
| Zoetis Inc. (ZTS)vs › | $31.59B | 81.75% | 66.19% | 56.82% | 52.60% |
ROE
31.5%
ROA
14.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 30.46% |
| 2024-12-31 | 27.40% |
| 2023-12-31 | 26.18% |
| 2022-12-31 | 16.01% |
| 2021-12-31 | 10.62% |
| 2020-12-31 | 27.02% |
| 2019-12-31 | 11.45% |
| 2018-12-31 | -19.16% |
| 2017-12-31 | -11.97% |
| 2016-12-31 | -23.11% |
| 2015-12-31 | -26.04% |
| 2014-12-31 | -15.98% |
| 2013-12-31 | -35.43% |
| 2012-12-31 | -70.78% |
| 2011-12-31 | -42.82% |
| 2010-12-31 | -90.45% |
| 2009-12-31 | 290.18% |
| 2008-12-31 | 283.46% |
| 2007-12-31 | -644.81% |
| 2006-12-31 | -82.00% |
| 2005-12-31 | -62.27% |
| 2004-12-31 | 28.28% |
| 2003-12-31 | 30.41% |
| 2002-12-31 | 0.00% |
| 2001-12-31 | 70.25% |
| 2000-12-31 | 124.26% |
